Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium
Abstract
Behavior/Comportment/Personality (BEHAV) and Language (LANG) domains were added to the Clinical Dementia Rating (CDR®) for improving evaluation of patients with frontotemporal lobar degeneration (FTLD) (CDR® plus NACC FTLD).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2020
- Source ID
- 10.1016/j.jalz.2019.05.013
Entities
People
- Adam Boxer
- Bradley Boeve
- Danielle Brushaber
- David Knopman
- Hilary W. Heuer
- Howie Rosen
- Jeremy Syrjanen
- John Kornak
- Julie Fields
- Leah K. Forsberg
- On Behalf Of The Artfl/lefftds Consortium
- Toji Miyagawa
- Walter Kremers
Organizations
- AbbVie
- Alzheimer Society of B.C.
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- AstraZeneca
- Avid Radiopharmaceuticals
- Biogen
- BrightFocus Foundation
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Centers for Disease Control and Prevention
- Eisai
- Eli Lilly and Company
- Hoffmann-La Roche
- Huntington's Disease Society of America
- Janssen Pharmaceuticals
- Mayo Clinic
- Merck & Co.
- National Institutes of Health
- New York State Department of Health
- Novartis
- Pfizer
- Roche (United States)
- Swedish Parkinson’s Disease Association
- The Michael J. Fox Foundation
- University of California, San Francisco
- Wyeth